Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Feb;214(2):339–358. doi: 10.1084/jem.20160596

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Mescher et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 8. — Human P-cadherin expression is associated with melanoma formation, progression, and reduced patient survival. (A) RNA expression profiling by microarray of human normal skin (n = 7 tissues from different donors), nevi (n = 18 tissues from different donors), and primary melanoma (n = 45 tumors from different patients) reveals increasing P-cadherin mRNA expression with tumor progression. Error bars: 95% confidence interval (Tukey’s posthoc test). *, P = 0.0152; ****, P < 0.0001; one-way ANOVA with Tukey’s posthoc test. The dataset is published by Talantov et al. (2005) under GEO accession no. GSE3819. (B) Profiling of mRNA expression (no. VALUE = MAS5 − calculated signal intensity after global scaling the mean intensity to 600) by microarray of normal skin (n = 7 tissues from different donors), nevi (n = 9 tissues from different donors), primary melanoma (n = 31 tumors from different patients), and metastatic melanoma (n = 73 tumors from different patients) reveals a trend of increasing P-cadherin mRNA expression with tumor progression, whereas P-cadherin mRNA levels are significantly reduced in metastatic samples compared with primary melanoma samples (95% confidence interval; Tukey’s posthoc test). ***, P = 0.001; one-way ANOVA with Tukey’s posthoc test. The dataset is published by Kabbarah et al. (2010) under GEO accession no. GSE46517. (C) P-cadherin mRNA expression is significantly increased in primary melanoma (n = 103 tumors) compared with metastatic melanoma (n = 368 tumors). 95% confidence interval (Tukey’s posthoc test). ****, P < 0.0001; Student’s t test. The Cancer Genome Atlas (TCGA) skin cutaneous melanoma (SKCM) dataset was used. (D) Patients with P-cadherin mRNA up-regulation (total n = 25 patients; number of cases deceased = 14) have worse overall survival compared with patients without alterations in P-cadherin expression (total n = 434 patients; number of cases deceased = 205). Median months survival: cases with P-cadherin alteration, 28.15 mo; cases without alteration, 81.14 mo. Up-ticks represent censored cases. P = 0.0104; log-rank (Mantel-Cox) test. TCGA SKCM dataset was used.